NEW YORK, NY / ACCESSWIRE / September 12, 2018 / Major equities closed up on Tuesday, with strong performances from the energy and telecommunications sector, as investors continued to watch the situation in the U.S. and China. The Dow Jones Industrial Average climbed 0.44 percent to close at 25,971.06, while the S&P 500 Index increased 0.37 percent to close at 2,887.89. The Nasdaq Composite Index gained 0.61 percent to close at 7,972.47.
“You have to watch the trade issue because global supply chains are so complex, and economic growth has depend on the efficiency of these chains,” according to Tom Plumb, chief investment officer of Plumb Funds. He further added, "Having said that, people talk about the trade issue as though nothing will happen, or as though the worst-case scenario will happen. We think it will be somewhere in between, and while I would stay away from emerging markets and China for a while, we have so much momentum in the U.S. that I would expect any correction to be short lived."
RDI Initiates Coverage on:
Momenta Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc.
Momenta Pharmaceuticals' stock jumped 5.92% Tuesday, to close the day at $27.75. The stock recorded a trading volume of 314,381 shares, which was below its three months average volume of 474,198 shares. In the last year, Momenta Pharmaceuticals' shares have traded in a range of 11.85 - 32.20. The share price has gained 134.18% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $27.65 is above its 200-day moving average of $22.79. Shares of Momenta Pharmaceuticals have gained roughly 6.81 percent in the past month and are up 98.92 percent year-to-date.
Access RDI's Momenta Pharmaceuticals, Inc. Research Report at:
On Tuesday, shares of Aerie Pharmaceuticals recorded a trading volume of 300,233 shares, which was below the three months average volume of 410,535 shares. The stock ended the day 3.45% higher at $58.40. The share price has fallen 21.87% from its 52 week high with a 52 week trading range of 47.05 - 74.75. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $64.29 is above its 200-day moving average of $59.32. Shares of Aerie Pharmaceuticals have fallen roughly 9.46 percent in the past month and are down 2.26 percent year-to-date.
Access RDI's Aerie Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.